Zimmer Biomet Holdings ROE 2006-2018 | ZBH
Current and historical return on equity (ROE) values for Zimmer Biomet Holdings (ZBH) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Zimmer Biomet Holdings ROE for the three months ending September 30, 2018 was 12.88%.
| Zimmer Biomet Holdings ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2018-09-30 | $1.75B | $12.22B | 14.61% |
| 2018-06-30 | $1.69B | $12.04B | 14.62% |
| 2018-03-31 | $1.69B | $12.00B | 15.19% |
| 2017-12-31 | $1.81B | $11.74B | 17.10% |
| 2017-09-30 | $0.65B | $10.45B | 6.47% |
| 2017-06-30 | $0.71B | $10.28B | 7.19% |
| 2017-03-31 | $0.50B | $9.93B | 5.11% |
| 2016-12-31 | $0.31B | $9.67B | 3.18% |
| 2016-09-30 | $0.36B | $9.75B | 3.75% |
| 2016-06-30 | $0.23B | $9.55B | 2.32% |
| 2016-03-31 | $0.08B | $9.66B | 0.85% |
| 2015-12-31 | $0.15B | $9.89B | 1.60% |
| 2015-09-30 | $0.17B | $9.99B | 2.02% |
| 2015-06-30 | $0.32B | $10.13B | 4.28% |
| 2015-03-31 | $0.67B | $6.58B | 10.26% |
| 2014-12-31 | $0.72B | $6.55B | 11.19% |
| 2014-09-30 | $0.83B | $6.54B | 12.96% |
| 2014-06-30 | $0.81B | $6.45B | 12.86% |
| 2014-03-31 | $0.78B | $6.24B | 12.75% |
| 2013-12-31 | $0.78B | $6.30B | 12.98% |
| 2013-09-30 | $0.68B | $6.14B | 11.49% |
| 2013-06-30 | $0.70B | $5.89B | 12.05% |
| 2013-03-31 | $0.77B | $5.71B | 13.23% |
| 2012-12-31 | $0.76B | $5.87B | 13.11% |
| 2012-09-30 | $0.76B | $5.83B | 13.38% |
| 2012-06-30 | $0.77B | $5.71B | 13.76% |
| 2012-03-31 | $0.76B | $5.66B | 13.38% |
| 2011-12-31 | $0.76B | $5.52B | 13.25% |
| 2011-09-30 | $0.64B | $5.61B | 11.01% |
| 2011-06-30 | $0.64B | $6.02B | 10.89% |
| 2011-03-31 | $0.60B | $5.86B | 10.37% |
| 2010-12-31 | $0.60B | $5.77B | 10.36% |
| 2010-09-30 | $0.72B | $5.82B | 12.52% |
| 2010-06-30 | $0.68B | $5.74B | 11.72% |
| 2010-03-31 | $0.72B | $5.71B | 12.45% |
| 2009-12-31 | $0.72B | $5.64B | 12.48% |
| 2009-09-30 | $0.73B | $5.98B | 12.70% |
| 2009-06-30 | $0.80B | $5.81B | 14.05% |
| 2009-03-31 | $0.81B | $5.56B | 14.54% |
| 2008-12-31 | $0.85B | $5.65B | 15.10% |
| 2008-09-30 | $0.95B | $5.62B | 16.96% |
| 2008-06-30 | $0.78B | $5.51B | 14.15% |
| 2008-03-31 | $0.78B | $5.71B | 14.38% |
| 2007-12-31 | $0.77B | $5.45B | 14.67% |
| 2007-09-30 | $0.76B | $5.25B | 14.68% |
| 2007-06-30 | $0.89B | $5.28B | 17.75% |
| 2007-03-31 | $0.86B | $5.12B | 17.47% |
| 2006-12-31 | $0.84B | $4.92B | 17.09% |
| 2006-09-30 | $0.79B | $4.80B | 16.37% |
| 2006-06-30 | $0.78B | $4.90B | 16.33% |
| 2006-03-31 | $0.77B | $4.92B | 16.64% |
| 2005-12-31 | $0.73B | $4.68B | 16.64% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $23.031B | $7.824B |
| Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. Zimmer Biomet Holdings, Inc., formerly known as Zimmer Holdings, Inc., is based in Warsaw, United States. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medtronic (MDT) | Ireland | $124.342B | 19.06 |
| Abbott Laboratories (ABT) | United States | $122.048B | 24.73 |
| Stryker (SYK) | United States | $62.796B | 23.67 |
| Boston Scientific (BSX) | United States | $50.730B | 25.64 |
| Baxter (BAX) | United States | $33.541B | 21.66 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.007B | 0.00 |
| ResMed (RMD) | United States | $14.492B | 27.64 |
| Canopy Growth (CGC) | Canada | $8.934B | 0.00 |
| Perrigo (PRGO) | Ireland | $8.884B | 13.48 |
| Bio-Rad Laboratories (BIO) | United States | $8.054B | 51.50 |
| Aurora Cannabis (ACB) | Canada | $6.462B | 35.26 |
| Hill-Rom Holdings (HRC) | United States | $6.201B | 19.66 |
| Haemonetics (HAE) | United States | $5.495B | 48.33 |
| Insulet (PODD) | United States | $4.770B | 0.00 |
| ICU Medical (ICUI) | United States | $4.529B | 25.23 |
| Hutchison China MediTech (HCM) | China | $4.274B | 0.00 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $3.987B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $3.869B | 0.00 |
| Neogen (NEOG) | United States | $3.219B | 48.74 |
| National Vision Holdings (EYE) | United States | $3.101B | 61.33 |
| NuVasive (NUVA) | United States | $2.972B | 27.65 |
| Aphria (APHA) | $2.572B | 0.00 | |
| Quidel (QDEL) | United States | $2.478B | 32.30 |
| NxStage Medical (NXTM) | United States | $1.924B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.476B | 20.89 |
| AtriCure (ATRC) | United States | $1.174B | 0.00 |
| Cardiovascular Systems (CSII) | United States | $1.015B | 1462.50 |
| VAREX IMAGING (VREX) | United States | $0.992B | 19.93 |
| Meridian Bioscience (VIVO) | United States | $0.827B | 26.35 |
| PetIQ (PETQ) | United States | $0.803B | 22.83 |
| OraSure Technologies (OSUR) | United States | $0.793B | 44.65 |
| Surmodics (SRDX) | United States | $0.776B | 118.55 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.755B | 24.22 |
| Cerus (CERS) | United States | $0.719B | 0.00 |
| MacroGenics (MGNX) | United States | $0.710B | 0.00 |
| Omeros (OMER) | United States | $0.623B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.590B | 18.27 |
| Owens & Minor (OMI) | United States | $0.558B | 6.31 |
| Insys Therapeutics (INSY) | United States | $0.542B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.518B | 25.45 |
| NanoString Technologies (NSTG) | United States | $0.481B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.438B | 0.00 |
| Evolus (EOLS) | United States | $0.399B | 0.00 |
| Quanterix (QTRX) | United States | $0.359B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.327B | 21.12 |
| Cytosorbents (CTSO) | United States | $0.302B | 0.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.255B | 0.00 |
| Surface Oncology (SURF) | United States | $0.226B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.211B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.206B | 278.75 |
| Bovie Medical (BVX) | United States | $0.201B | 0.00 |
| Chimerix (CMRX) | United States | $0.161B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.148B | 0.00 |
| Fonar (FONR) | United States | $0.139B | 6.96 |
| Chembio Diagnostics (CEMI) | United States | $0.104B | 0.00 |
| Imprimis Pharmaceuticals (IMMY) | United States | $0.081B | 0.00 |
| United-Guardian (UG) | United States | $0.079B | 16.63 |
| Female Health (VERU) | United States | $0.079B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.077B | 24.40 |
| Oramed Pharmaceuticals (ORMP) | Israel | $0.070B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.067B | 0.00 |
| CAS Medical Systems (CASM) | United States | $0.056B | 0.00 |
| Neurotrope (NTRP) | United States | $0.050B | 0.00 |
| ImmuCell (ICCC) | United States | $0.041B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.028B | 0.00 |
| Myomo (MYO) | United States | $0.025B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.021B | 0.00 |
| Senestech (SNES) | United States | $0.019B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.019B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.007B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.000B | 0.00 |
